No Data
Hunan Fangsheng Pharmaceutical (SHSE:603998) Has A Pretty Healthy Balance Sheet
Hunan Fangsheng Pharmaceutical (603998.SH): The products are expected to be selected for the national Chinese Patent Medicine procurement alliance's centralized volume procurement.
On January 2, Gelonghui reported that Hunan Fangsheng Pharmaceutical (603998.SH) announced that the company and its subsidiary Hunan Xiangya Pharmaceutical Co., Ltd. (referred to as 'Xiangya Pharmaceutical') participated in the national Chinese Patent Medicine procurement alliance centralized procurement work. According to the announcement released by the Hubei Medical Insurance Service Platform on the evening of December 30, 2024, the proposed selection results for the national Chinese Patent Medicine procurement alliance centralized procurement (first batch expansion continuation) indicate that Xuesaitong tablets are among the proposed selected products.
Hunan Fangsheng Pharmaceutical (603998.SH): A wholly-owned subsidiary has been recognized as a high-tech enterprise.
Gelonghui reported on December 17th that Hunan Fangsheng Pharmaceutical (603998.SH) announced that on December 17, 2024, the Office of the Leading Group for the Management of National High-Tech Enterprise Recognition issued a notice regarding the second batch of high-tech enterprises' acknowledgment from Guangdong Province for 2024. The company's wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Fangsheng Jianmeng"), has been recognized as a high-tech enterprise, with certificate number GR202444006126, issuance date on November 28, 2024, and a validity period of three years. Fangsheng Jianmeng has been recognized as a high-tech enterprise this time.
Hunan Fangsheng Pharmaceutical (603998.SH): Changes occurred in the partnership shares of the merger and acquisition Fund established through investments.
On December 16, Gelonghui reported that Hunan Fangsheng Pharmaceutical (603998.SH) announced that on December 13, 2024, the company received a notice from Zhuhai Hengqin Zhongke Jianchuang Investment Partnership (Limited Partnership) (referred to as "Zhongke Jianchuang"). Zhongke Jianchuang agreed to allow Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. (referred to as "Maipu Technology") to subscribe for an additional partner share of 26.49 million yuan for 30 million yuan, and the company waived its right of first refusal. This change in the partner share of Zhongke Jianchuang does not harm the company's interests, and the number of partner shares held by the company has not changed (partner shares.
Hunan Fangsheng Pharmaceutical (603998.SH): Product renewal in the national medical insurance catalog (2024).
On November 28, 2023, Hunan Fangsheng Pharmaceutical (603998.SH) announced that on November 28, 2024, the National Medical Insurance Administration and the Ministry of Human Resources and Social Security issued the notice regarding the "Publication of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Pharmaceutical Catalog (2024)" [Medical Insurance Issue No. 33 (2024)] (hereinafter referred to as the "2024 Edition of the Medical Insurance Catalog"). According to this notice, the company's pediatric Jingxing cough granules and Xuanqi bone-strengthening tablets will be included in the "2024 Edition of the Medical Insurance Catalog" during the negotiation renewal period, and there are no withdrawals or additions for the company's other major products and those of its controlling subsidiaries this time.
zhongtai: In Q3 2024, traditional chinese medicine companies are experiencing temporary pressure, while end demand has slightly rebounded.
In the third quarter of 2024, traditional chinese medicine companies are experiencing temporary performance pressure, but gross margin is expected to improve upward from 2025.
Investors Don't See Light At End Of Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) Tunnel And Push Stock Down 29%